MMP13 is a potential prognostic marker for colorectal cancer

Oncology Reports

Volumn 24, Issue 5, 2010, Pages 1241-1247

  Huang, Ming Yii ^a,b   Chang, Hui Jen ^c,d   Chung, Fu Yen ^b   Yang, Ming Je ^b   Yang, Yu Hsiang ^d   Wang, Jaw Yuan ^a,b   Lin, Shiu Ru ^c,d  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c FOOYIN UNIVERSITY   (Taiwan)

^d FOOYIN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Colorectal cancer; MMP13; Prognostic marker

Indexed keywords

COLLAGENASE 3; MESSENGER RNA;

ADULT; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER INVASION; CANCER PATIENT; CANCER RELAPSE; CANCER TISSUE; CELL MEMBRANE; CLINICAL FEATURE; COLORECTAL CANCER; COLORECTAL SURGERY; CONTROLLED STUDY; CULTURE MEDIUM; CYTOPLASM; DISEASE SEVERITY; FEMALE; GENE EXPRESSION; GENE OVEREXPRESSION; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; IN VITRO STUDY; IN VIVO STUDY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; POSTOPERATIVE COMPLICATION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; PROTEIN LOCALIZATION; PROTEIN SECRETION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR VOLUME; WESTERN BLOTTING;

COLORECTAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MATRIX METALLOPROTEINASE 13; MIDDLE AGED; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL;

EID: 78149290610     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or-00000978     Document Type: Article

References (39)

1. Parkin DM: Global cancer statistics in the year 2000. Lancet Oncol 2: 533-543, 2001.
2. Ghafoor A, Jemal A, Cokkinides V, Cardinez C, Murray T, Samuels A and Thun MJ: Cancer statistics for African Americans. CA Cancer J Clin 52: 326-341, 2002.
3. Department of Health TEY: Republic of China 2007 health statistics. Retrieved from (http://www.Doh.Gov.Tw/statistic/index.Htm).
4. Smith RA, Cokkinides V and Eyre HJ: Cancer screening in the united states, 2007: a review of current guidelines, practices, and prospects. CA Cancer J Clin 57: 90-104, 2007.
5. Pohl C, Hombach A and Kruis W: Chronic inflammatory bowel disease and cancer. Hepatogastroenterology 47: 57-70, 2000.
6. Greenlee RT, Murray T, Bolden S and Wingo PA: Cancer statistics, 2000. CA Cancer J Clin 50: 7-33, 2000.
7. McLeod HL and Murray GI: Tumour markers of prognosis in colorectal cancer. Br J Cancer 79: 191-203, 1999.
8. Curran S and Murray GI: Matrix metalloproteinases in tumour invasion and metastasis. J Pathol 189: 300-308, 1999.
9. Curran S and Murray GI: Matrix metalloproteinases: molecular aspects of their roles in tumour invasion and metastasis. Eur J Cancer 36: 1621-1630, 2000.
10. Lafleur MA, Handsley MM and Edwards DR: Metalloproteinases and their inhibitors in angiogenesis. Expert Rev Mol Med 5: 1-39, 2003.
11. Ala-aho R, Ahonen M, George SJ, Heikkila J, Grenman R, Kallajoki M and Kahari VM: Targeted inhibition of human collagenase-3 (MMP-13) expression inhibits squamous cell carcinoma growth in vivo. Oncogene 23: 5111-5123, 2004.
12. Lafleur MA, Drew AF, de Sousa EL, Blick T, Bills M, Walker EC, Williams ED, Waltham M and Thompson EW: Upregulation of matrix metalloproteinases (MMPs) in breast cancer xenografts: a major induction of stromal MMP-13. Int J Cancer 114: 544-554, 2005.
13. Culhaci N, Metin K, Copcu E and Dikicioglu E: Elevated expression of MMP-13 and TIMP-1 in head and neck squamous cell carcinomas may reflect increased tumor invasiveness. BMC Cancer 4: 42, 2004.
14. Gearing AJ, Beckett P, Christodoulou M, Churchill M, Clements J, Davidson AH, Drummond AH, Galloway WA, Gilbert R and Gordon JL: Processing of tumour necrosis factor-alpha precursor by metalloproteinases. Nature 370: 555-557, 1994.
15. Overall CM, McQuibban GA and Clark-Lewis I: Discovery of chemokine substrates for matrix metalloproteinases by exosite scanning: a new tool for degradomics. Biol Chem 383: 1059-1066, 2002.
16. Van den Steen PE, Proost P, Grillet B, Brand DD, Kang AH, Van Damme J and Opdenakker G: Cleavage of denatured natural collagen type II by neutrophil gelatinase b reveals enzyme specificity, post-translational modifications in the substrate, and the formation of remnant epitopes in rheumatoid arthritis. FASEB J 16: 379-389, 2002.
17. Itoh Y and Nagase H: Matrix metalloproteinases in cancer. Essays Biochem 38: 21-36, 2002.
18. Yu AE, Hewitt RE, Connor EW and Stetler-Stevenson WG: Matrix metalloproteinases. Novel targets for directed cancer therapy. Drugs Aging 11: 229-244, 1997.
19. Lynch CC smf Matrisian LM: Matrix metalloproteinases in tumor-host cell communication. Differentiation 70: 561-573, 2002.
20. Knauper V, Lopez-Otin C, Smith B, Knight G and Murphy G: Biochemical characterization of human collagenase-3. J Biol Chem 271: 1544-1550, 1996.
21. Mori D, Nakafusa Y, Miyazaki K and Tokunaga O: Differential expression of Janus kinase 3 (JAK3), matrix metalloproteinase 13 (MMP13), heat shock protein 60 (HSP60), and mouse double minute 2 (MDM2) in human colorectal cancer progression using human cancer cdna microarrays. Pathol Res Pract 201: 777-789, 2005.
22. Roeb E, Arndt M, Jansen B, Schumpelick V and Matern S: Simultaneous determination of matrix metalloproteinase (MMP)-7, MMP-1, -3, and -13 gene expression by multiplex PCR in colorectal carcinomas. Int J Colorectal Dis 19: 518-524, 2004.
23. Leeman MF, McKay JA and Murray GI: Matrix metalloproteinase 13 activity is associated with poor prognosis in colorectal cancer. J Clin Pathol 55: 758-762, 2002.
24. International Union against Cancer. TNM classification of malignant tumors. 6th edition. Wiley-Liss inc., New York, 2002.
25. Janku F, Srovnal J, Korinkova G, Novotny J, Petruzelka L, Power D, Matous B and Hajduch M: Molecular detection of disseminated breast cancer cells in the bone marrow of early breast cancer patients using quantitative RT PCR for CEA. Neoplasma 55: 317-322, 2008.
26. Chen YF, Shin SJ and Lin SR: Ets1 was significantly activated by ERK1/2 in mutant K-ras stably transfected human adrenocortical cells. DNA Cell Biol 24: 126-132, 2005.
27. Chen YF, Wang JY, Wu CH, Chen FM, Cheng TL and Lin SR: Detection of circulating cancer cells with K-ras oncogene using membrane array. Cancer Lett 229: 115-122, 2005.
28. Sternlicht MD and Werb Z: How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 17: 463-516, 2001.
29. Sato H, Takino T, Okada Y, Cao J, Shinagawa A, Yamamoto E and Seiki M: A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature 370: 61-65, 1994.
30. MacDougall JR and Matrisian LM: Contributions of tumor and stromal matrix metalloproteinases to tumor progression, invasion and metastasis. Cancer Metastasis Rev 14: 351-362, 1995.
31. Johansson N, Airola K, Grenman R, Kariniemi AL, Saarialho-Kere U and Kahari VM: Expression of collagenase-3 (matrix metalloproteinase-13) in squamous cell carcinomas of the head and neck. Am J Pathol 151: 499-508, 1997.
32. Heppner KJ, Matrisian LM, Jensen RA and Rodgers WH: Expression of most matrix metalloproteinase family members in breast cancer represents a tumor-induced host response. Am J Pathol 149: 273-282, 1996.
33. Airola K, Karonen T, Vaalamo M, Lehti K, Lohi J, Kariniemi AL, Keski-Oja J and Saarialho-Kere UK: Expression of collagenases-1 and -3 and their inhibitors TIMP-1 and -3 correlates with the level of invasion in malignant melanomas. Br J Cancer 80: 733-743, 1999.
34. Luukkaa M, Vihinen P, Kronqvist P, Vahlberg T, Pyrhonen S, Kahari VM and Grenman R: Association between high collagenase-3 expression levels and poor prognosis in patients with head and neck cancer. Head Neck 28: 225-234, 2006.
35. Morgia G, Falsaperla M, Malaponte G, Madonia M, Indelicato M, Travali S and Mazzarino MC: Matrix metalloproteinases as diagnostic (MMP-13) and prognostic (MMP-2, MMP-9) markers of prostate cancer. Urol Res 33: 44-50, 2005.
36. Nielsen BS, Rank F, Lopez JM, Balbin M, Vizoso F, Lund LR, Dano K and Lopez-Otin C: Collagenase-3 expression in breast myofibroblasts as a molecular marker of transition of ductal carcinoma in situ lesions to invasive ductal carcinomas. Cancer Res 61: 7091-7100, 2001.
37. Thompson EW, Paik S, Brunner N, Sommers CL, Zugmaier G, Clarke R, Shima TB, Torri J, Donahue S and Lippman ME: Association of increased basement membrane invasiveness with absence of estrogen receptor and expression of vimentin in human breast cancer cell lines. J Cell Physiol 150: 534-544, 1992.
38. Wang TN, Qian X, Granick MS, Solomon MP, Rothman VL, Berger DH and Tuszynski GP: Thrombospondin-1 (TSP-1) promotes the invasive properties of human breast cancer. J Surg Res 63: 39-43, 1996.
39. Giambernardi TA, Grant GM, Taylor GP, Hay RJ, Maher VM, McCormick JJ and Klebe RJ: Overview of matrix metalloproteinase expression in cultured human cells. Matrix Biol 16: 483-496, 1998.